RNAZ
Transcode Therapeutics Inc
NASDAQ: RNAZ · HEALTHCARE · BIOTECHNOLOGY
$8.01
-4.64% today
Updated 2026-04-30
Market cap
$7.75M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-52.59
Dividend yield
—
52W range
$6 – $22
Volume
0.0M
Transcode Therapeutics Inc (RNAZ) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | $42470.00 | $98606.00 | $516746.00 | $534857.00 | $114177.00 |
| Gross profit | — | — | — | $-42470.00 | $-98606.00 | $-516746.00 | $-534857.00 | $-114177.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $82532.00 | $226309.00 | $284459.00 | $2.75M | $10.23M | $12.26M | $9.62M | $13.42M |
| SG&A | $301464.00 | $230556.00 | $442145.00 | $3.40M | $8.43M | $7.15B | $5.95M | $5.77M |
| Operating income | $-383996.00 | $-456865.00 | $-726604.00 | $-6.15M | $-18.67M | $-19.42M | $-15.66M | $-27.98M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-69444.00 | $-450247.00 | $-1.95M | $-6.71M | $-17.47M | $-17.97M | $-16.19M | $-34.31M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-453440.00 | $-456865.00 | $-1.45M | $-6.75M | $-17.56M | $-18.49M | $-16.73M | $-34.43M |
| Interest expense | $0.00 | $156965.00 | $394573.00 | $95070.00 | $17.56M | $55899.00 | $26813.00 | $6616.00 |
| Income tax | $-69444.00 | $156931.00 | $394437.00 | $95070.00 | $17.56M | $4.00 | $-16.79B | — |
| Effective tax rate | 13.3% | -34.9% | -20.2% | -1.4% | — | -0.0% | 99.9% | 0.0% |
| Net income | $-453440.00 | $-607212.00 | $-2.34M | $-6.84M | $-17.56M | $-18.55M | $-16.75M | $-34.66M |
| Net income growth (YoY) | — | -33.9% | -286.0% | -192.0% | -156.7% | -5.6% | +9.7% | -106.9% |
| Profit margin | — | — | — | — | — | — | — | — |